Acquired idiopathic inflammatory myopathy

This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…

This Phase 1 trial tests the safety and tolerability of a new drug called AZD5492 in 72 adults with lupus, myositis, or rheumatoid arthritis. Participants receive one or two doses under the skin and are monitored for side effects and how the drug moves through the body. The study…

This trial tests an investigational cell therapy called FT839 in people with active autoimmune diseases, including ANCA-associated vasculitis, inflammatory myositis, rheumatoid arthritis, lupus, and systemic sclerosis. Participants receive FT839 as two intravenous infusions, some…

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…

This study tests the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis, rare diseases that cause muscle weakness and rashes. Participants who completed a previous study can join. Some will receive the drug via IV every 4 weeks for abo…

This study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…

This early-phase trial is testing a new biologic drug called XmAb657 in 60 people, including healthy volunteers and those with autoimmune diseases like scleroderma, Sjögren's disease, and idiopathic inflammatory myopathies. The main goal is to check safety and how the body handle…

This early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…

This phase 2 trial tests a therapy called AlloNK, made from donor cord blood immune cells, combined with the drug rituximab. It aims to see if this combination is safe and can help people with severe forms of rheumatoid arthritis, Sjögren's disease, myositis, or scleroderma that …

This early-stage trial tests a new treatment called AZD0120 for adults with three autoimmune diseases: systemic sclerosis, idiopathic inflammatory myopathies, or difficult-to-treat rheumatoid arthritis. AZD0120 is made from a patient's own immune cells, which are modified in a la…

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This early-stage study tests a new drug (GSK5926371) in people with lupus and similar autoimmune diseases. The drug is designed to target and calm specific immune cells that attack the body. The main goal is to check if the drug is safe and how the body handles it, with 54 adults…

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…

This phase 2 trial is testing whether filgotinib, a drug already used for arthritis, can help people with three rare immune diseases: Behçet's disease, myositis, and IgG4-related disease. The goal is to see if it can control disease activity and reduce the need for long-term ster…

This early-phase trial is testing a new cell therapy called QH103 for people with severe autoimmune diseases like multiple sclerosis and myasthenia gravis that haven't responded to standard treatments. The therapy uses specially engineered immune cells to target and attack the fa…

This study tests whether stem cells from umbilical cord lining can safely reduce symptoms of dermatomyositis and polymyositis, two autoimmune diseases that cause muscle weakness and inflammation. About 40 adults will receive three doses of stem cells or a placebo, then switch. Re…

This early-stage trial is testing a new biologic drug called CC312 in just 6 adults with lupus, myositis, or scleroderma that has not responded to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive multip…

This early study tests the safety of a new biologic drug called STR-P004 in 39 adults with autoimmune diseases that have not responded to standard treatments. Participants receive the drug by IV infusion, and researchers monitor for side effects and how the drug behaves in the bo…

This early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This early-stage trial is testing a new treatment called LUCAR-G79D for people with lupus or inflammatory myopathies that haven't responded to standard therapies. The treatment involves giving patients specially engineered immune cells to help control their disease. The study is …

This early-stage trial tests a new treatment for people with autoimmune diseases like lupus and multiple sclerosis that haven't responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and destroy the faulty cells causing the d…

This early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …

This early-phase study tests whether a combination of two drugs, pozelimab and cemdisiran, can improve physical function in people with sporadic inclusion body myositis (sIBM), a rare muscle disease that causes progressive weakness. Ten adults aged 45 to 75 with sIBM will receive…

This early-stage trial tests a treatment called CAR-T cell therapy for people with severe autoimmune diseases that haven't responded to other treatments. The therapy uses a patient's own immune cells, modified to target and reset the immune system. Only 3 participants will be enr…

This early-phase study tests a new cell therapy called BZE2204 in 20 people with lupus, myositis, or immune thrombocytopenia (ITP) that has not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and calm the overactive immune syste…

This study tests whether a daily 3-month breathing exercise program can improve strength and daily function in people with inflammatory myopathy, a rare autoimmune disease that causes muscle weakness. Thirty-three adults will use a handheld device at home to strengthen their brea…

This study aims to discover biological markers (biomarkers) that could help doctors diagnose and track neurological autoimmune diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barre syndrome. Researchers will analyze samples from 50,000 people, including patie…

This study is building a library of information and samples from 60 adults with suspected autoimmune myopathy, a rare muscle disease. Researchers will collect blood, urine, stool, and muscle tissue, along with medical data, to better understand the condition. The goal is to impro…

This study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…

This study looks at whether a doctor's computer tool (MedSafer) and patient brochures (EMPOWER) can help reduce the use of potentially harmful medications in adults aged 60 and older with rheumatic diseases who take five or more regular drugs. Researchers will follow 100 particip…

This study asks 700 people with rare myositis diseases (and their caregivers) what research questions matter most to them. Through online surveys and forums, the goal is to create a patient-driven list of priorities to guide future studies and funding. No drugs or treatments are …

This study aims to find a way to predict which cancer patients will experience side effects from immunotherapy. These side effects happen when the immune system attacks healthy tissues, similar to autoimmune diseases. Researchers will collect blood samples from 300 cancer patient…